Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

NEW YORK, NY, Sept. 15 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova"), a cancer drug acquisition and development company, is pleased to announce it has gained access to distribution channels for its promising drug targets through a recently-signed deal with Bridge BioResearch Plc. ("Bridge BioResearch"). GENova expects to generate licensing fees and royalties from the out-licensed manufacturing and marketing rights to leading pharmaceutical companies to exceed more than 5% in a market currently valued at $3billion+ a year over the following 15-20 years which is the duration of the patents.

Bridge BioResearch is an international drug discovery company that focuses on metabolic disorders, and has well-established distribution channels and relationships with leading pharmaceutical companies.

Through a recent collaboration deal, the two companies are working together to leverage their respective Research and Development partners and distribution channels worldwide, with the mutual goal of developing their proprietary drug targets with the utmost cost and time efficiency.

The two companies are both in the business of acquiring early-stage developmental drugs, out-licensing them for development and commercialization, and garnering royalty payments in the process. GENova's focus is oncology, while Bridge BioResearch specializes in Obesity and Type 2 Diabetes drugs. Both companies share a mutual goal of fast-tracking their target drugs through development, clinical studies, licensing to Big Pharma such as Biogen, Elan, Merck's and Genentech.

"This reciprocal arrangement is a huge benefit to both companies," says Aaron Whiteman, CEO for GENova. "I am confident that with our new access to Big Pharma distribution channels we can usher our promising patents through the development process as expeditiously as possible, and ultimately start reaping royalty payments sooner than ever foreseen."

About Bridge BioResearch

Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants. To learn more about Bridge BioResearch, visit www.bridgebioresearch.com.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen , Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... MIAMI, FLA (PRWEB) , ... February 12, 2016 , ... ... free dental implants to their Miami dental office. Beginning in January, Miami Dental ... traditional titanium. Miami Dental Specialists are the first office to be chosen by the ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today ... , The print component of “Revolutionizing Cancer Care” is distributed within the February ... and Seattle, with a circulation of approximately 250,000 copies and an estimated readership ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have ... possibilities. CertainTeed, North America’s leading brand of building products, has improved upon its ... in the mobile version of the ColorView® Exterior Style and Color Selector. Created ...
(Date:2/12/2016)... ... 12, 2016 , ... Healthcare careers in the medical laboratory, nursing, and in ... website of healthcare staffing leader Aureus Medical Group during the month of January. Aureus ... therapy positions and in travel and direct hire opportunities in other allied health ...
(Date:2/12/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... real facts surrounding all those Bible stories. For generations families have gathered to hear ... says there is more to these than just mere “stories”. , The article ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
(Date:2/11/2016)... 11, 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ... the lives of pets, today announced the submission to ... Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  ... of Zimeta for the control of pyrexia (fever) in ... --> --> The Chemistry, Manufacturing, ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
Breaking Medicine Technology: